Bioiberica’s joint healthcare division and heparin business unit participated at the CPhl Russia fair, one of the most important events for the pharmaceutical sector
The Russian pharmaceutical market is growing at a 10 percent annual rate, and is expected to reach 25 Billion Dollars by 2018
A study published in the Molecules journal endorsed the efficacy of pharmaceutical-grade chondroitin for the treatment of osteoarthritis
Our company was granted “good” qualification within the A Group, the one formed by companies having their own manufacturing and R&D center in Spain
During this event, Bioiberica met with leading firms in the field of cosmetics in order to explore possible collaboration opportunities